EP0519986A1 - Polypeptides synthetiques - Google Patents
Polypeptides synthetiquesInfo
- Publication number
- EP0519986A1 EP0519986A1 EP91906077A EP91906077A EP0519986A1 EP 0519986 A1 EP0519986 A1 EP 0519986A1 EP 91906077 A EP91906077 A EP 91906077A EP 91906077 A EP91906077 A EP 91906077A EP 0519986 A1 EP0519986 A1 EP 0519986A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- gly
- amino acid
- leu
- ala
- ser
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 161
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 143
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 133
- 241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 78
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 46
- 101710091045 Envelope protein Proteins 0.000 claims abstract description 20
- 101710188315 Protein X Proteins 0.000 claims abstract description 20
- 208000031886 HIV Infections Diseases 0.000 claims abstract description 12
- 230000000890 antigenic effect Effects 0.000 claims abstract description 12
- 208000037357 HIV infectious disease Diseases 0.000 claims abstract description 11
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims abstract description 11
- 238000011321 prophylaxis Methods 0.000 claims abstract description 6
- 239000012634 fragment Substances 0.000 claims abstract 9
- 238000000034 method Methods 0.000 claims description 47
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 claims description 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 19
- 150000001413 amino acids Chemical class 0.000 claims description 18
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 239000002671 adjuvant Substances 0.000 claims description 11
- 239000000427 antigen Substances 0.000 claims description 10
- 108091007433 antigens Proteins 0.000 claims description 10
- 102000036639 antigens Human genes 0.000 claims description 10
- 239000000969 carrier Substances 0.000 claims description 8
- 229960005486 vaccine Drugs 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 230000000903 blocking effect Effects 0.000 claims description 5
- 230000001413 cellular effect Effects 0.000 claims description 5
- 238000005859 coupling reaction Methods 0.000 claims description 5
- 230000037029 cross reaction Effects 0.000 claims description 5
- 239000004030 hiv protease inhibitor Substances 0.000 claims description 5
- 210000000987 immune system Anatomy 0.000 claims description 5
- 230000004936 stimulating effect Effects 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 230000008878 coupling Effects 0.000 claims description 4
- 238000010168 coupling process Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 108020004414 DNA Proteins 0.000 claims description 3
- 238000009007 Diagnostic Kit Methods 0.000 claims description 3
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims description 3
- 230000036039 immunity Effects 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 102000053602 DNA Human genes 0.000 claims description 2
- 108020004511 Recombinant DNA Proteins 0.000 claims description 2
- 238000010188 recombinant method Methods 0.000 claims 3
- NPDLYUOYAGBHFB-WDSKDSINSA-N Asn-Arg Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N NPDLYUOYAGBHFB-WDSKDSINSA-N 0.000 claims 2
- 229940122440 HIV protease inhibitor Drugs 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 229910020788 La—F Inorganic materials 0.000 claims 1
- 238000005516 engineering process Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 7
- 238000003745 diagnosis Methods 0.000 abstract description 3
- 102100021696 Syncytin-1 Human genes 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 description 18
- 229940024606 amino acid Drugs 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 17
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 16
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 14
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 10
- 210000002540 macrophage Anatomy 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 241001494479 Pecora Species 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 208000030507 AIDS Diseases 0.000 description 8
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 8
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 230000002788 anti-peptide Effects 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
- -1 lie Chemical compound 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- 229940070741 purified protein derivative of tuberculin Drugs 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 description 3
- 238000013456 study Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 108010003079 GPGPGP peptide Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- 108010043293 glycyl-prolyl-glycyl-glycine Proteins 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- MXHCPCSDRGLRER-UHFFFAOYSA-N pentaglycine Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(O)=O MXHCPCSDRGLRER-UHFFFAOYSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000014599 transmission of virus Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
- OIXLLKLZKCBCPS-RZVRUWJTSA-N (2s)-2-azanyl-5-[bis(azanyl)methylideneamino]pentanoic acid Chemical compound OC(=O)[C@@H](N)CCCNC(N)=N.OC(=O)[C@@H](N)CCCNC(N)=N OIXLLKLZKCBCPS-RZVRUWJTSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- YVOOPGWEIRIUOX-UHFFFAOYSA-N 2-azanyl-3-sulfanyl-propanoic acid Chemical compound SCC(N)C(O)=O.SCC(N)C(O)=O YVOOPGWEIRIUOX-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108010010369 HIV Protease Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 238000012375 Ion exchange chromatography - high performance liquid chromatography Methods 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 101800005164 Peptide V Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 208000010648 susceptibility to HIV infection Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the present invention relates to synthetic polypeptides. It particularly relates to synthetic polypeptides which emulate the three-dimensional structures and/or electrostatic surfaces and/or other physical, chemical and structural properties of specific regions of viral envelope proteins. It is of particular interest to the design of vaccines, immunologically active therapeutic agents, diagnostics and other medical or scientific agents in relation to the Human Immunodeficiency Virus (HIV) known to be the causative agent of Acquired Immune Deficiency Syndrome (AIDS) .
- HIV Human Immunodeficiency Virus
- AIDS Acquired Immune Deficiency Syndrome
- An object of the present invention is the development of synthetic polypeptides which can elicit the production of antibodies to the HIV virus, and most preferably neutralising antibodies, that is, antibodies which prevent infection by and/or limit the spread of the HIV virus by passive or active immunisation. Passive immunisation with such antibodies may constitute an effective means of treatment of AIDS patients thus controlling the spread of the virus within and between individuals and hence slow or halt the progress of the disease.
- Our invention provides a synthetic polypeptide having at least one antigenic property of the envelope protein of at least one strain of Human Immunodeficiency Virus (HIV) , said polypeptide consisting substantially of an amino acid sequence of formula (I):-
- R 1 is Asp or Glu
- R- is an amino acid residue selected from
- R 3 is an amino acid residue selected from Gly, Ala, Pro, Ser, Thr, Asp, Glu, Asn, Lys, His, Gin or Arg;
- R 4 , R 5 and R.,. are each independently any amino acid residue;
- R 6 and R 8 are each independently an amino acid residue selected from Gly, Ala, Pro, Ser, Thr, or Asn;
- R 7 is an amino acid residue selected from Gly, Ala, Val, Leu, lie, Ser, Thr, Asn, Gin, Phe, Tyr, Trp, Cys, Met or Pro;
- R_ and R 12 are each independently an amino acid residue selected from Gly,
- R 10 is an amino acid residue selected from Lys, His or Arg; and X and Y may each independently be absent or independently be one or more, e.g. 3, additional amino acid residues.
- Peptides according to formula I above without X and Y being present will of course be useful, for example, in the production of antibodies to the HIV. However, when X or Y are present they may be any length but preferably less than 20 amino acids, more preferably less than 10, eg. 3 to 6. It will of course be appreciated that the sequence according to formula I may constitute a protein with X and Y being major portions of the protein with the antigenic sequence being for example, part of an exposed loop on a globular protein.
- R 2 is selected from Gin or Thr
- R 3 is selected from Ser, Asn, Gin, Arg or Ala
- R is selected from Leu, lie, Gin or Arg
- R 5 is either Leu or Lys
- R 6 is either Gly or Asn
- R 7 is selected from Gly, Ala, Leu, lie, Val, Met, Cys, Phe, Tyr, Trp or Ser
- R- is either Ser or Ala
- R g is either Gly or Phe
- R 10 is either Arg or Lys
- R. is selected from Leu, His, lie
- Gin and R 12 is selected from Ala, lie or Val.
- the Cys residues at positions 10 and 16 may optionally be linked by an intra-molecular disulphide bridge.
- One preferred form of polypeptide according to the invention consists substantially of an amino acid sequence of formula (II) :-
- R 3 , R 5 , R n , R 12 , X and Y are as defined above; and R 7 is an amino acid residue selected from
- R 3 is selected from Ser, Asn, Gin and Arg, R is selected from Leu, His or lie and R 12 is lie or Ala.
- R 7 is selected from lie, Phe, Met, Val or Leu. More preferably R- is either Ser or Asn and R 5 is Lys.
- polypeptide of formula (II) consists of the sequence:-
- polypeptide of Formula 5 (II) comprises R 3 selected from Gin or Arg, R 5 is Leu, R 7 is selected from lie, Phe and Met, R ⁇ is selected from Leu, His or lie, and R 12 is Ala.
- a preferred sequence has the formula:-
- polypeptide according to the invention consists substantially of an amino acid sequence of formula (III):- 20
- R 1 is either Glu or Asp
- R 2 is Thr or Gin
- 25 R 3 is an amino acid selected from Ser, Asn
- R 4 is an amino acid selected from Leu, He, Arg or Gin; R ⁇ is Lys or Leu; and 30 wherein X and Y are as defined above, and the Cys residues at positions 10 and 16 may optionally be linked by an intra-molecular disulphide bridge.
- a preferred form of a polypeptide according to 3 . 5 Formula III consists substantially of an amino acid sequence of formula (Ilia) :- X-Glu-Thr-R 3 -R 4 -Lys-Asn-Ser-Trp-Gly- Cys-Ala-Phe-Arg-Gln-Val-Cys-Y
- R 3 is an amino acid residue selected from Ser, Asn, Arg, Gin or Ala
- 4 is an amino acid residue selected from Leu, He, Arg or Gin
- X and Y are as defined above, and the Cys residues at positions 10 and 16 may optionally be linked by an intra-molecular disulphide bridge, it is preferred that R 3 is Ser when R 4 is He and when R 3 is Ala R 4 is either Arg or Gin but preferably Arg.
- Polypeptides according to formula III are similar to certain epitopes of HIV II envelope proteins.
- Preferred polypeptide sequences according to the invention were chosen on the basis of their topographical similarity to more than one antigenic determinant of the HIV envelope proteins.
- an antigenic determinant to which a given polypeptide was originally designed to be an analogue may also show topographical similarity to one or more other regions of the HIV envelope proteins possibly due to duplication of ancestral genes, or because the polypeptide is an analogue of a discontinuous determinant, or because the polypeptides have been designed to be polyvalent.
- a discontinuous epitope may be viewed as being composed of closely opposed sequential epitopes which may be of antigenic significance in their own right and a polyvalent polypeptide may contain two or more (continuous or discontinuous) determinant analogues in a single polypeptide chain, thus providing a means to simultaneously elicit the production of a range of antibodies which will recognise two or more determinants on the HIV envelope proteins.
- Peptides according to the invention may be synthesised for example using either standard 9- fluorenyl-methoxycarbonyl (F-Moc) chemistry (see, for example, Atherton, E. and Sheppard, R. C. (1985) J. Chem. Soc. Chem. Comm.
- Polypeptides according to the invention or antibodies thereto may be administered on their own or with other agents such as 3 '-azido-3 '-deoxythymidine (AZT) (zidovudine) , which acts at a different level by interfering with the replication of the genetic material of the virus, and/or HIV protease inhibitors, which block the action of an enzyme essential to the development of the virus.
- ZT 3 '-azido-3 '-deoxythymidine
- HIV protease inhibitors which block the action of an enzyme essential to the development of the virus.
- Polypeptides according to the invention may be used to raise antibodies which will cross-react with envelope proteins produced by a wide range of HIV I and/or HIV II strains. Our analyses have shown that since the conformational/topographic/electrostatic properties of polypeptides according to the invention are such that they are highly likely to elicit the production of antibodies which will cross-react with HIV envelope proteins from several or many strains, further advantages may arise from combining several variant polypeptides in a larger polypeptide.
- Such a polypeptide may have the general formula (IV) :
- F and G may each independently be a polypeptide according to any one of Formulae I to Ilia
- L is a linking sequence
- a, b and c are each independently 0 or 1 and and n are each positive numbers e.g. between 1 and 10 inclusive.
- L is preferably a short, conformationally flexible section of polypeptide chain such as, for example and without limit Gly-Gly-Gly-Gly- Gly, Gly-Pro-Gly-Pro-Gly-Pro or Gly-Ser-Ala-Gly-Ser-Gly- Ala. It should be clear that each repeat may optionally have a different variant of a polypeptide according to the invention.
- Polyvalent determinant analogues as defined by Formula IV are referred to as pseudohomopolyvalent, wherein variants of essentially the same determinant analogue are repeated in a single polypeptide chain.
- pseudohomopolyvalent polypeptide im unogens which contain multiple copies of the same variant of one of the determinant analogues according to any one of formulae I to Ilia, would also be expected to be effective, and are also included within the scope of the present invention.
- Pseudohomopolyvalent immunogenic polypeptides are expected to be particularly valuable as vaccines, where they should elicit the production of a range of (neutralising) antibodies with a similar but non-identical underlying specificity, which between them would cross-react with envelope protein from a wider range of HIV strains, and would thus be more effective at conferring protective immunity.
- heteropolyvalent polypeptides which contain one or more copies, in any order, of one of the polypeptides according to the present invention and one or more other polypeptide analogues of determinant analogues.
- Such polypeptides which are provided for in the present invention, have the general formula (V) :
- F is a polypeptide according to any one of Formulae I to Ilia
- G is a polypeptide according to any one of Formulae I to Ilia or other sequence
- m and n are each positive numbers e.g. between 1 and 10 inclusive
- d and e are each independently 0 or 1.
- L is preferably a short, conformationally flexible section of polypeptide chain such as, for example and without limit Gly-Gly-Gly-Gly-Gly, Gly-Pro-Gly-Pro-Gly-Pro or Gly-Ser-Ala-Gly-Ser-Gly-Ala.
- G may comprise a polypeptide according to any one of Formula I to Ilia or the sequence:
- each Gly may independently be replaced with any other amino acid and/or X and Y may each independently be absent or one or more e.g. three amino acid residues or G may comprise some other polypeptide sequence related to antigenic proteins from HIV.
- any antigenically significant subfragments and/or antigenically significant variants of the above-identified polypeptide sequences which retain the general form and function of the parent polypeptide are included within the scope of this invention.
- the substitution of any of the specific residues by residues having comparable conformational and/or physical properties, including substitution by rare (but naturally occurring, e.g. D-stereoisomers) or synthetic amino acid analogues is included.
- substitution of a residue by another in the same Set is included within the ambit of the invention; Set 1 - Ala, Val, Leu, He, Phe, Tyr, Trp and Met; Set 2 - Ser, Thr, Asn and Gin; Set 3 - Asp and Glu; Set 4 - Lys, His and Arg; Set 5 - Asn and Asp; Set 6 - Glu and Gin; Set 7 - Gly, Ala, Pro, Ser and Thr.
- D-stereoisomers of all amino acid types may be substituted, for example, D-Phe, D-Tyr and D-Trp.
- X and Y if present may independently include one or more segments of protein sequence with the ' ability to act as a T-cell epitope.
- Lys, Arg, His, Glu, Asp, Asn, Gin, Ser, Thr, Pro appear to act as T-cell epitopes in at least some instances (Rothbard, J.B. & Taylor, W.R. (1988) . A sequence pattern in common to T-cell epitopes. The EMBO Journal 7(1): 93-100). Similarly segments can be of the sequence 1'-2 '-3 '-4 '-5 ' , wherein 1' is equivalent to 1 as defined earlier, 2 1 to 2 , 3' and 4' to 3, and 5 ' to 4 (ibid) .
- T-cell epitopes preferably less than five which may be of the type defined above or may be of other structure and which may be separated by spacer segments of any length or composition, preferably less than five amino acid residues in length and comprising for example residues selected from Gly, Ala, Pro, Asn, Thr, Ser or polyfunctional linkers such as non- amino acids. It is possible for a C- or N-terminal linker to represent a complete protein, thus obviating the possible need for conjugation to a carrier protein. Also included within the scope of this invention are derivatives of the polypeptide according to formula I in which X or Y are or include a "retro-inverso" amino acid, i.e. a bifunctional amine having a functional group corresponding to an amino acid. For example an analogue according to the invention and containing a retro-inverso amino acid may have the formula:
- R is any functional group, e.g. a glycine side chain
- Al and A2 are preferably each a copy of one of the analogues defined herein (but not necessarily the same) attached by its N- or C-terminal end.
- T-cell epitopes may optionally be included as discussed earlier.
- Retro-inverso modification of peptides involves the reversal of one or more peptide bonds to create analogues more resistant than the original molecule to enzymatic degradation and offer one convenient route to the generation of branched immunogens which contain a high concentration of epitope for a medium to large immunogen.
- the use of these compounds in large-scale solution synthesis of retro-inverso analogues of short- chain biologically active peptides has great potential. It should be noted that analogues incorporating retro-inverso amino acid derivatives cannot be made directly using a recombinant DNA system.
- the basic analogues can, and they can then be purified and chemically linked to the retro-inverso amino-acids using standard peptide/organic chemistry.
- a practical and convenient novel procedure for the solid-phase synthesis on polyamide-type resin of retro-inverso peptides has been described recently [Gazerro, H. , Pinori, M. & Verdini, A.S. (1990).
- polypeptides are optionally linked to a carrier molecule, either through chemical groups within the polypeptides themselves or through additional amino acids added at either the C- or N-terminus, and which may be separated from the polypeptides themselves or surrounded by one or more additional amino acids, in order to render them optimal for their immunological function.
- linkages are suitable and include for example use of the side chains of Tyr, Cys and Lys residues.
- Suitable carriers include, for example, purified protein derivative of tuberculin (PPD) , tetanus toxoid, cholera toxin and its B subunit, ovalbumin, bovine serum albumin, soybean trypsin inhibitor, muramyl dipeptide and analogues thereof, and Braun's lipoprotein although other suitable carriers will be readily apparent to the skilled person.
- PPD tuberculin
- tetanus toxoid cholera toxin and its B subunit
- ovalbumin bovine serum albumin
- soybean trypsin inhibitor muramyl dipeptide and analogues thereof
- Braun's lipoprotein although other suitable carriers will be readily apparent to the skilled person.
- PPD is expected to be a preferred carrier for use in such countries.
- the mode of coupling the polypeptide to the carrier will depend on the nature of the materials to be coupled.
- a lysine residue in the carrier may be coupled to a C-terminal or other cysteine residue in a polypeptide by treatment with N- 7 -maleimidobutyryloxy-succinimide (Kitagawa, T. & Ackawa, T. (1976) J. Biochem. 79 . , 233) .
- Other coupling reactions and reagents have been described in the literature.
- polypeptides may be administered by any route (eg parenteral, nasal, oral, rectal, intra-vaginal) , with or without the use of conventional adjuvants (such as aluminium hydroxide or Freund•s complete or incomplete adjuvants) and/or other immunopotentiating agents.
- the invention also includes formulation of polypeptides according to the invention in slow-release forms, such as a sub-dermal implant or depot comprising, for example, liposomes (Allison, A.C. & Gregoriadis, G. (1974) Nature (London) 252, 252) or biodegradable microcapsules manufactured from co-polymers of lactic acid and glycolic acids (Gresser, J. D. and Sanderson, J. E. (1984) in "Biopolymer Controlled Release Systems” pp 127-138, Ed. D. L. Wise).
- polypeptides according to the invention may be synthesised by any conventional method, either directly using manual or automated peptide synthesis techniques as mentioned above, or indirectly by RNA or DNA synthesis and conventional techniques of molecular biology and genetic engineering. Such techniques may be used to produce hybrid proteins containing one or more of the polypeptides inserted into another polypeptide sequence.
- Another aspect of the present invention therefore provides a DNA molecule coding for at least one synthetic polypeptide according to the invention, preferably incorporated into a suitable expression vector replicable in microorganisms or in mammalian cells.
- the DNA may also be part of the DNA sequence for a longer product e.g. the polypeptides may be expressed as parts of other proteins into which they have been inserted by genetic engineering.
- One practical guide to such techniques is "Molecular cloning: a laboratory manual" by Sambrook, J., Fritsch, E.F. and Maniatis, T. (2nd Edition, 1989) .
- Polypeptides according to the invention may be used either alone or linked to an appropriate carrier, as:
- antigenic agents for the generation of monoclonal or polyclonal antibodies by immunisation of an appropriate animal such antibodies being of use for (i) the scientific study of the HIV virus, (ii) as diagnostic agents, e.g. as part of histochemical reagents, (iii) for the passive immunisation of HIV patients, either as a treatment for AIDS in itself, or in combination with other agents such as, for example
- AZT and/or HIV protease inhibitors as a means of targeting other agents (e.g. AZT or HIV protease inhibitors) to HIV infected cells expressing HIV envelope proteins on their surfaces, such agents either being linked covalently or otherwise associated, e.g. as in liposomes containing such agents and incorporating antibodies raised against any of the antigenic polypeptides.
- agents e.g. AZT or HIV protease inhibitors
- the invention further provides for genetically engineered forms or sub-components, especially V H regions, of antibodies raised against the polypeptides, and of humanised forms of antibodies initially raised against the polypeptides in other animals, using techniques described in the literature; and (e) The treatment of HIV infections, either by displacing the binding of HIV virus to human or animal cells or by disturbing the three-dimensional organisation of the virus in vivo; as well as aiding the scientific study of HIV viruses in vitro.
- detection and diagnosis, of HIV or antibodies against HIV the skilled person will be aware of a variety of immunoassay techniques known in the art, inter alia, sandwich assay, competitive and non- competitive assays and the use of direct and indirect labelling.
- a further aspect of the invention provides a kit for detecting HIV or antibodies against HIV which comprises at least one synthetic polypeptide according to the invention.
- Antibodies according to the invention are, inter alia, of use in a method of diagnosing mammalian HIV infection which comprises incubating a sample of tissue or body fluid of mammal with an effective amount of antibody as described herein and determining whether, and if desired the extent to which and/or rate at which, cross-reaction between said sample and said antibody occurs. Diagnostic kits which contain at least one of said antibodies also form part of this invention.
- a further aspect of the invention provides synthetic polypeptides for use in therapy or prophylaxis of mammalian HIV infection and/or stimulating the mammalian immune system and/or blocking the cellular receptors for the HIV virus and for the preparation of medicaments suitable for such uses.
- pharmaceutical compositions containing, as active ingredient, at least one polypeptide or polypeptide-carrier conjugate as described herein in association with one or more pharmaceutically acceptable adjuvants, carriers and/or excipients.
- the compositions may be formulated for oral, rectal, nasal or especially parenteral administration (including intra-CNS administration) .
- the invention further provides a method of therapy or prophylaxis of mammalian HIV infection and/or of stimulating the mammalian immune system and/or of blocking the cellular receptors for the HIV virus, which comprises administering an effective amount of a polypeptide as hereinbefore defined, either in isolation or in combination with other agents for the treatment of AIDS such as AZT and/or inhibitors of the HIV protease.
- a polypeptide as hereinbefore defined, either in isolation or in combination with other agents for the treatment of AIDS such as AZT and/or inhibitors of the HIV protease.
- Example 1 A C-terminally extended form of basic peptide (a) with sequence
- the peptide was dissolved in phosphate-buffered saline (PBS; 5mg/ml) and mixed with an equal volume of ovalbumin (5mg/ml) prior to the addition of glutaraldehyde to a final concentration of 0.1%(w/v).
- PBS phosphate-buffered saline
- ovalbumin 5mg/ml
- the conjugate mixture was allowed to stand for 30 minutes prior to emulsification with Freund's adjuvant.
- Each sheep was immunised with 250 ⁇ g of peptide in Freund's complete adjuvant (FCA) and subsequently (14 days) challenged with a further similar quantity in Freund's incomplete adjuvant (FIA) . Further challenges were performed after a period of 3-4 weeks in FIA.
- CVl monkey kidney cells grown in monolayer cultures in 96-well microtitre plates, were infected with the recombinant vaccinia virus.
- the virus construct contained the gene encoding the HIV envelope glycoprotein and this is known to be processed and expressed on the surface of the infected cells.
- Antisera from sheep were assayed in duplicate. A quantity of 50 ⁇ l of antiserum at various dilutions was added to the wells and incubated for 4 hours prior to washing (twice) and adding a second peroxidase-labelled anti-sheep antiserum.
- Example 2 One role of neutralising antibodies is to inhibit the transmission of virus from infected to non-infected cells. Preventing or reducing the rate of transmission of virus from T-cells to macrophages is crucial since this may extend the life of AIDS patients considerably Anti-peptide antisera were assayed for their ability to inhibit syncitia formation in vitro. Syncitia are multinucleated giant cells which result from "bridge"-formation between HIV-infected cells.
- the anti-peptide antisera were used in an in vitro HIV neutralisation assay.
- the anti-peptide antibodies were introduced into an in vitro culture of human T-lymphocytes infected with a highly virulent strain of HIV, and uninfected human macrophages.
- the anti-peptide antisera were found to inhibit syncitia formation amongst this mixed population of T-cells and macrophages exposed to a virulent -strain of HIV I, i.e. they inhibit spread of HIV infection from T-cell to macrophage.
- the antibodies were found to prevent infection of the macrophages with HIV, and are therefore neutralising in this in vitro assay, whereas the macrophages became infected in a control culture, as shown in Table 2.
- Table 2 Neutralisation of virulent strain of HIV in in vitro culture of HIV-infected human T-lymphocytes and uninfected human macrophages. "+++” indicates a high level of infection and "-" indicates effective protection against infection.
- positive antisera to peptide (a) were evaluated in a syncitium assay. This assay determines the capability of antisera to prevent spread of live HIV from infected to uninfected cells and to prevent fusion between cells mediated through reactivity between the virus glycoprotein (gpl60) and the CD4 molecule. Measurement is carried out by syncitium detection and enumeration.
- the syncitium assay is performed as follows: a known concentration of an HIV producer (CD+4) cell line supporting active virus replication is washed three times and mixed with the antiserum under test and used at specified dilutions. After incubation for 30 minutes at 37"C these cells are mixed, at specified proportions with an indicator CD4+ cell line, highly susceptible to HIV infection and syncitium induction. The cells are observed daily for syncitium formation.
- CD+4 HIV producer
- Antibodies to peptide(a) were found to inhibit syncitium formation as shown in Table 3.
- Anti-peptide (a) antiserum + (3/5 animals) Normal sheep serum
- the ELISA procedure determines the degree of reactivity of the synthetic peptides (analogous to regions of either gpl20 or the gp41 transmembrane protein of HIV-l) with antibody to the surface glycoprotein of HIV-l in sera of HIV-l positive individuals.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- AIDS & HIV (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Les peptides synthétiques décrits comprennent au moins une propriété antigénique de la protéine enveloppe d'au moins une souche du virus d'immuno-deficience humaine (HIV). Une séquence préférée est: X-Asp-Gln-Ser-Leu-Lys-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ala-Cys-Y, où X et Y peuvent, l'un indépendamment de l'autre, être absents ou être un ou plusieurs résidus d'acides aminés additionnels, et les résidus Cys situés aux positions 10 et 16 peuvent être facultativement liés par un pont de disulfure intramoléculaire. Lesdits polypeptides peuvent être utilisés pour le diagnostic, le traitmeent et la prophylaxie de l'infection HIV. On décrit également des anticorps et les fragments de liaison qui se lient spécifiquement aux peptides.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB909005829A GB9005829D0 (en) | 1990-03-15 | 1990-03-15 | Synthetic polypeptides |
GB9005829 | 1990-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0519986A1 true EP0519986A1 (fr) | 1992-12-30 |
Family
ID=10672665
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP91906077A Withdrawn EP0519986A1 (fr) | 1990-03-15 | 1991-03-13 | Polypeptides synthetiques |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP0519986A1 (fr) |
JP (1) | JPH05505188A (fr) |
CN (1) | CN1054772A (fr) |
AP (1) | AP211A (fr) |
AU (1) | AU636735B2 (fr) |
BR (1) | BR9106159A (fr) |
CA (1) | CA2078220A1 (fr) |
CS (1) | CS68091A2 (fr) |
FI (1) | FI923800A (fr) |
GB (1) | GB9005829D0 (fr) |
HU (1) | HUT63179A (fr) |
IL (1) | IL97551A0 (fr) |
MX (1) | MX24890A (fr) |
NZ (1) | NZ237417A (fr) |
OA (1) | OA09671A (fr) |
WO (1) | WO1991013909A1 (fr) |
ZA (1) | ZA911886B (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993009252A1 (fr) * | 1991-11-04 | 1993-05-13 | Baxter Diagnostics Inc. | Peptides synthetiques correspondant a des portions du virus vih-2 et procedes d'utilisation de ces peptides dans une analyse amelioree |
US5395750A (en) * | 1992-02-28 | 1995-03-07 | Hoffmann-La Roche Inc. | Methods for producing proteins which bind to predetermined antigens |
US5888992A (en) * | 1992-03-11 | 1999-03-30 | Narhex Limited | Polar substituted hydrocarbons |
ATE253050T1 (de) | 1992-03-11 | 2003-11-15 | Narhex Ltd | Aminderivate von oxo- und hydroxy- substituierten kohlenwasserstoffen |
WO1993018006A1 (fr) * | 1992-03-11 | 1993-09-16 | Narhex Limited | Derives amines d'hydrocarbures a substitution oxo et hydroxy |
US6071895A (en) * | 1992-03-11 | 2000-06-06 | Narhex Limited | Polar-substituted hydrocarbons |
GB9208428D0 (en) * | 1992-04-16 | 1992-06-03 | Proteus Molecular Design | Synthetic polypeptides |
US6511845B1 (en) | 1992-08-07 | 2003-01-28 | Alan R. Davis | Methods for producing an immune response against HIV-1 |
DE69333397T2 (de) | 1992-08-27 | 2004-12-09 | Bioclones (Proprietary) Ltd., Sandton | Retro-, inverso-, und retro-inverso synthetische peptidanaloge |
DE4402756A1 (de) * | 1994-01-31 | 1995-08-03 | Boehringer Mannheim Gmbh | Spezifische Bindungssubstanzen für Antikörper und deren Verwendung für Immunoassays oder Vakzine |
AUPM411994A0 (en) * | 1994-02-25 | 1994-03-24 | Deakin Research Limited | Epitopes |
US6764682B1 (en) * | 1994-06-16 | 2004-07-20 | Aventis Pasteur Limited | Adjuvant compositions containing more than one adjuvant |
US6290971B1 (en) | 1995-06-15 | 2001-09-18 | Aventis Pasteur Limited | Adjuvant compositions comprising a mineral salt and another immunostimulating compound |
CN1472314A (zh) * | 2002-07-29 | 2004-02-04 | 清华大学 | 艾滋病病毒o型株的一个免疫学表位及其应用 |
CN100445296C (zh) * | 2006-03-31 | 2008-12-24 | 浙江大学 | 多肽有机化合物及其在异种移植中的应用 |
WO2010057197A1 (fr) | 2008-11-17 | 2010-05-20 | The Regents Of The University Of Michigan | Compositions de vaccins contre le cancer et leurs méthodes d’utilisation |
GB201612108D0 (en) | 2016-07-12 | 2016-08-24 | Univ Strathclyde | Preperation of non-ionic surfactant vesicles and variants |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8714802D0 (en) * | 1987-06-24 | 1987-07-29 | Proteus Biotech Ltd | Synthetic polypeptides |
EP0316695B1 (fr) * | 1987-11-16 | 1993-03-31 | F. Hoffmann-La Roche Ag | Polypeptides recombinants de HIV-2 |
-
1990
- 1990-03-15 GB GB909005829A patent/GB9005829D0/en active Pending
-
1991
- 1991-03-13 EP EP91906077A patent/EP0519986A1/fr not_active Withdrawn
- 1991-03-13 JP JP3505817A patent/JPH05505188A/ja active Pending
- 1991-03-13 NZ NZ237417A patent/NZ237417A/en unknown
- 1991-03-13 WO PCT/GB1991/000392 patent/WO1991013909A1/fr not_active Application Discontinuation
- 1991-03-13 CA CA002078220A patent/CA2078220A1/fr not_active Abandoned
- 1991-03-13 BR BR919106159A patent/BR9106159A/pt not_active Application Discontinuation
- 1991-03-13 MX MX2489091A patent/MX24890A/es unknown
- 1991-03-13 AU AU74679/91A patent/AU636735B2/en not_active Ceased
- 1991-03-13 HU HU922939A patent/HUT63179A/hu unknown
- 1991-03-14 IL IL97551A patent/IL97551A0/xx unknown
- 1991-03-14 ZA ZA911886A patent/ZA911886B/xx unknown
- 1991-03-14 AP APAP/P/1991/000245A patent/AP211A/en active
- 1991-03-15 CS CS91680A patent/CS68091A2/cs unknown
- 1991-03-15 CN CN91101549A patent/CN1054772A/zh active Pending
-
1992
- 1992-08-24 FI FI923800A patent/FI923800A/fi not_active Application Discontinuation
- 1992-09-11 OA OA60275A patent/OA09671A/en unknown
Non-Patent Citations (1)
Title |
---|
See references of WO9113909A1 * |
Also Published As
Publication number | Publication date |
---|---|
ZA911886B (en) | 1991-12-24 |
IL97551A0 (en) | 1992-06-21 |
AP9100245A0 (en) | 1991-04-30 |
FI923800A0 (fi) | 1992-08-24 |
AU7467991A (en) | 1991-10-10 |
FI923800A (fi) | 1992-08-24 |
AU636735B2 (en) | 1993-05-06 |
NZ237417A (en) | 1993-10-26 |
BR9106159A (pt) | 1993-03-16 |
HU9202939D0 (en) | 1992-12-28 |
WO1991013909A1 (fr) | 1991-09-19 |
JPH05505188A (ja) | 1993-08-05 |
CS68091A2 (en) | 1991-12-17 |
OA09671A (en) | 1993-05-15 |
AP211A (en) | 1992-10-21 |
GB9005829D0 (en) | 1990-05-09 |
MX24890A (es) | 1993-12-01 |
HUT63179A (en) | 1993-07-28 |
CN1054772A (zh) | 1991-09-25 |
CA2078220A1 (fr) | 1991-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2201421C2 (ru) | Синтетический пептид hiv (варианты), иммуногенная композиция для индукции иммунного ответа против пептидов hiv, диагностический набор для определения hiv-специфичных антител | |
US8110203B2 (en) | Adjuvant comprising non-toxic cross-linked muramyl dipeptide (MDP) microparticles derived from Propionibacterium acnes | |
AP211A (en) | Synthetic polypeptides. | |
AU650911B2 (en) | Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus | |
EP0740792B1 (fr) | Peptomeres a immunogenicite accrue | |
JPH089636B2 (ja) | Htlv−iii/lavウイルス関連ペプチド | |
AU3960493A (en) | Synthetic polypeptides derived from the HIV envelope glycoprotein | |
AU2006200454B2 (en) | Compositions and methods for treating viral infections | |
AU6515394A (en) | Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus | |
KR100348183B1 (ko) | 텐덤합성hiv-1펩티드들 | |
Syennerholm et al. | Vahlne et al. | |
AU6655300A (en) | Compositions and methods for treating infections | |
AU2006200455A1 (en) | Compositions and methods for treating viral infections | |
AU2004208648A1 (en) | Compositions and methods for treating infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19921002 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: PROTEUS MOLECULAR DESIGN LIMITED |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Withdrawal date: 19950306 |